Kalvista Pharmaceuticals Company Insiders

KALV Stock  USD 10.15  0.83  8.91%   
Slightly above 53% of Kalvista Pharmaceuticals' sophisticated investors are presently acquiring. The analysis of the overall insider sentiment regarding Kalvista Pharmaceuticals suggests that some insiders are bullish. Kalvista Pharmaceuticals employs about 150 people. The company is managed by 14 executives with a total tenure of roughly 21 years, averaging almost 1.0 years of service per executive, having 10.71 employees per reported executive.
Benjamin Palleiko  President
Chief President

Kalvista Pharmaceuticals' Insider Buying Vs Selling

53

 
Selling
 
Buying

Latest Trades

2024-11-18Benjamin L PalleikoDisposed 14400 @ 9.26View
2024-09-09Benjamin L PalleikoDisposed 7352 @ 12.19View
2024-08-23Paul K AudhyaDisposed 2135 @ 12.4View
2024-08-19Christopher YeaDisposed 7102 @ 12.01View
2024-06-07Benjamin L PalleikoDisposed 7465 @ 11.53View
2024-05-20Edward P FeenerDisposed 8088 @ 11.76View
2024-02-20Edward P FeenerDisposed 28288 @ 14.07View
2024-02-08Venrock Healthcare Capital ParAcquired 29747 @ 14.7View
2024-02-06Venrock Healthcare Capital ParAcquired 4474 @ 14.74View
2024-01-29Venrock Healthcare Capital ParAcquired 80600 @ 14.22View
2024-01-26Venrock Healthcare Capital ParAcquired 4174 @ 12.98View
2024-01-24Venrock Healthcare Capital ParAcquired 20686 @ 12.44View
2024-01-22Venrock Healthcare Capital ParAcquired 67546 @ 12.55View
2024-01-18Venrock Healthcare Capital ParAcquired 39680 @ 12.51View
2024-01-16Venrock Healthcare Capital ParAcquired 19599 @ 12.73View
Monitoring Kalvista Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.

Kalvista Pharmaceuticals' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Kalvista Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Kalvista will maintain a workforce of slightly above 150 employees by December 2024.
 
Covid

Kalvista Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.5394) % which means that it has lost $0.5394 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9084) %, meaning that it created substantial loss on money invested by shareholders. Kalvista Pharmaceuticals' management efficiency ratios could be used to measure how well Kalvista Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Kalvista Pharmaceuticals' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.16 in 2024, whereas Return On Tangible Assets are likely to drop (1.09) in 2024. At this time, Kalvista Pharmaceuticals' Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 1 M in 2024, whereas Other Current Assets are likely to drop slightly above 1 M in 2024.
Common Stock Shares Outstanding is likely to climb to about 38.6 M in 2024, whereas Net Loss is likely to drop (26.1 M) in 2024.

Kalvista Pharmaceuticals Workforce Comparison

Kalvista Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 3,859. Kalvista Pharmaceuticals holds roughly 150 in number of employees claiming about 4% of equities under Health Care industry.

Kalvista Pharmaceuticals Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kalvista Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kalvista Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Kalvista Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-12-01
0.6667
8
12
 110,225 
 89,894 
2024-09-01
0.3889
7
18
 183,968 
 124,661 
2024-06-01
0.3636
8
22
 281,848 
 197,145 
2024-03-01
1.0
36
36
 2,414,704 
 493,227 
2023-12-01
0.3636
8
22
 624,321 
 191,175 
2023-09-01
0.5217
12
23
 173,294 
 189,375 
2023-06-01
0.4
6
15
 76,971 
 53,805 
2023-03-01
0.5789
11
19
 317,244 
 72,818 
2022-12-01
0.9
9
10
 54,191 
 19,089 
2022-09-01
0.25
3
12
 9,996 
 26,931 
2022-03-01
0.6667
2
3
 57,657 
 67,657 
2021-09-01
1.25
5
4
 50,000 
 21,000 
2021-06-01
0.4444
16
36
 676,558 
 400,896 
2021-03-01
0.7895
15
19
 391,142 
 125,284 
2020-12-01
0.8095
17
21
 587,044 
 90,316 
2019-12-01
0.5833
7
12
 28,355 
 24,710 
2019-09-01
2.2
11
5
 135,002 
 28,010 
2019-06-01
0.4074
11
27
 201,828 
 221,938 
2019-03-01
0.0851
4
47
 21,355 
 1,373,239 
2018-12-01
0.4
4
10
 28,000 
 60,440 
2018-09-01
9.0
9
1
 1,491,148 
 2,500 
2017-12-01
0.3333
3
9
 2,265,065 
 2,725,283 
2017-09-01
1.0
7
7
 42,000 
 353,291 
2016-12-01
1.8
18
10
 7,482,195 
 79,801 
2015-12-01
0.5
1
2
 10,000 
 20,000 
2015-06-01
1.6552
48
29
 30,130,798 
 10,321,258 

Kalvista Pharmaceuticals Notable Stakeholders

A Kalvista Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kalvista Pharmaceuticals often face trade-offs trying to please all of them. Kalvista Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kalvista Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Benjamin PalleikoChief PresidentProfile
Stephen DonnellyDirector SecretaryProfile
Jarrod AldomVice CommunicationsProfile
Nicole SweenyChief OfficerProfile
Ryan BakerHead RelationsProfile
Brian PiekosChief OfficerProfile
John McKuneVP FinProfile
Thomas MBACEO DirectorProfile
Michael PharmDSenior DevelopmentProfile
Christopher YeaChief Development OfficerProfile
MD MBAChief OfficerProfile
Rachel MortenSenior QAProfile
Edward FeenerChief Scientific OfficerProfile
Brian JDGeneral CounselProfile

About Kalvista Pharmaceuticals Management Performance

The success or failure of an entity such as Kalvista Pharmaceuticals often depends on how effective the management is. Kalvista Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kalvista management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kalvista management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.54)(1.09)
Return On Capital Employed(0.66) 18.02 
Return On Assets(0.54)(1.09)
Return On Equity(0.61) 0.16 
Please note, the imprecision that can be found in Kalvista Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kalvista Pharmaceuticals. Check Kalvista Pharmaceuticals' Beneish M Score to see the likelihood of Kalvista Pharmaceuticals' management manipulating its earnings.

Kalvista Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Kalvista Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kalvista Pharmaceuticals within its industry.

Kalvista Pharmaceuticals Manpower Efficiency

Return on Kalvista Pharmaceuticals Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee844.3K
Net Loss Per Executive9M
Working Capital Per Employee1.4M
Working Capital Per Executive14.5M

Additional Tools for Kalvista Stock Analysis

When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.